EFFECTIVENESS OF VENETOСLAX IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (LITERATURE REVIEW)

EFFECTIVENESS OF VENETOСLAX IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (LITERATURE REVIEW)

Currently we are facing a revolution in therapy of chronic lymphocytic leukemia, related to the development of novel target drugs, which have markedly improved treatment results in all groups of patients. While inhibitors of Bruton’s tyrosine kinase (ibrutinib, acalabrutinib etc.) and phosphatidylin...

Full description

Bibliographic Details
Main Authors:	V. V. Strugov, E. A. Stadnik, A. Yu. Zaritskey
Format:	Article
Language:	Russian
Published:	ABV-press 2018-02-01
Series:	Онкогематология
Subjects:	chronic lymphocytic leukemia venetoclax antiapoptotic protein bcl-2
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/263

Similar Items

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia
by: Wing Fai Li, et al.
Published: (2024-11-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment
by: A. V. Rudakova, et al.
Published: (2020-04-01)

Efficacy and safety of venetoclax in relapsed/refractory chronic lymphocytic leukemia in Russia routine clinical practice
by: E. A. Dmitrieva, et al.
Published: (2024-09-01)

Prognosis and new therapeutic approaches in chronic lymphocytic leukemia treatment
by: Otašević Vladimir, et al.
Published: (2019-01-01)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
by: Courtney Samuels, et al.
Published: (2022-05-01)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017-03-01)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
by: Francesco Angotzi, et al.
Published: (2022-02-01)

MODERN APPROACHES TO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
by: A. A. Danilenko, et al.
Published: (2020-12-01)

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
by: Valeria J. Sarapura Martinez, et al.
Published: (2023-03-01)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
by: Sasanka Handunnetti, et al.
Published: (2021-05-01)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019-03-01)

Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia
by: Samir Mouhssine, et al.
Published: (2024-04-01)

Treatment strategy in chronic lymphocytic leukemia with symptomatic central nervous system involvement: A case report
by: Rosina Dewaide, et al.
Published: (2023-11-01)

Treatment with Venetoclax for Chronic Lymphocytic Leukemia with the Highest Known White Blood Cell Count: Safe and Effective
by: Mehmet Sönmez, et al.
Published: (2021-12-01)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
by: Jeffrey P. Sharman, et al.
Published: (2022-05-01)

BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies
by: Mariam Markouli, et al.
Published: (2025-01-01)

RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?
by: Antonio Cuneo, et al.
Published: (2019-02-01)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
by: Valerio Guarente, et al.
Published: (2021-09-01)

Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease
by: Hiroyuki Sugiura, et al.
Published: (2022-04-01)

A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)
by: O. A. Rukavitsyn, et al.
Published: (2022-11-01)

BAX/BCL2 ratio in chronic lymphocytic leukemia and its association with ZAP-70 expression and other clinicopathological parameters
by: Rihab Malik Rahid, et al.
Published: (2020-01-01)

Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Acute Myeloid Leukemia Secondary to Chronic Lymphocytic Leukemia After Prolonged Chlorambucil Therapy: A Case Report
by: Wu Y, et al.
Published: (2023-04-01)

SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01)

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges
by: Sofija Kozarac, et al.
Published: (2025-01-01)

Overview of recent developments in chronic lymphocytic leukemia
by: Preetesh Jain, et al.
Published: (2012-01-01)

Biclonal chronic lymphocytic leukemia: A study of two cases and review of literature
by: Kiran Ashok Ghodke, et al.
Published: (2017-01-01)

Effect of Berberine on Bcl-2 Expression in Chronic Lymphocytic Leukemia Compared with Healthy Controls
by: Mehrnoosh Pashaei, et al.
Published: (2019-03-01)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
by: Qingfang Li, et al.
Published: (2019-06-01)

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
by: Stefania Fiorcari, et al.
Published: (2022-01-01)

Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease “sanctuary” during venetoclax treatment?
by: Maria Dimou, et al.
Published: (2021-04-01)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
by: Natalia Timofeeva, et al.
Published: (2023-05-01)

mRNA in situ hybridization analysis of p-53 cancer suppression gene and Bcl-2 oncogene in chronic lymphocytic leukemia
by: Abdulkareem M. Jaafar, et al.
Published: (2010-07-01)

Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia
by: Giovanni Belcari, et al.
Published: (2022-07-01)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
by: Nishika Karbhari, et al.
Published: (2022-03-01)

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia
by: Juan Li, et al.
Published: (2025-12-01)

Meningeal involvement in chronic lymphocytic leukemia
by: S. N. Menshakova, et al.
Published: (2022-11-01)